Home Cart Sign in  
Chemical Structure| 40045-50-9 Chemical Structure| 40045-50-9

Structure of SU3327
CAS No.: 40045-50-9

Chemical Structure| 40045-50-9

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Selective JNK inhibitor

Synonyms: Halicin

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of SU3327

CAS No. :40045-50-9
Formula : C5H3N5O2S3
M.W : 261.30
SMILES Code : O=[N+](C1=CN=C(SC2=NN=C(N)S2)S1)[O-]
Synonyms :
Halicin
MDL No. :MFCD01927019
InChI Key :NQQBNZBOOHHVQP-UHFFFAOYSA-N
Pubchem ID :11837140

Safety of SU3327

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H315-H319
Precautionary Statements:P264-P280-P302+P352+P332+P313+P362+P364-P305+P351+P338+P337+P313

Related Pathways of SU3327

MAPK
TLR

Isoform Comparison

Biological Activity

Target
  • JNK1

    JNK, IC50:0.7 μM

  • JNK

    JNK, IC50:0.7 μM

  • JNK2

    JNK, IC50:0.7 μM

  • JNK3

    JNK, IC50:0.7 μM

In Vitro:

Cell Line
Concentration Treated Time Description References
Actinobacillus pleuropneumoniae S6 2 μg/ml (MIC90) 24 hours Evaluate the antibacterial activity of SU3327, showing significant antibacterial effects Antibiotics (Basel). 2024 May 27;13(6):492
S. aureus ATCC 29213 8 µg/mL (MIC90) 24 hours Evaluate the antibacterial activity of SU3327, showing significant antibacterial effects Antibiotics (Basel). 2024 May 27;13(6):492
E. coli ATCC 25922 8 µg/mL (MIC90) 24 hours Evaluate the antibacterial activity of SU3327, showing significant antibacterial effects Antibiotics (Basel). 2024 May 27;13(6):492
H9c2 embryonic rat cardiomyocytes 10 µM 30 minutes To evaluate the effects of SU3327 on cell viability, ROS levels, and mitochondrial membrane potential under H2O2-induced oxidative stress. Results showed that SU3327 increased cell death and ROS levels and decreased mitochondrial membrane potential. PLoS One. 2014 Nov 25;9(11):e113526

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Mice CCl4-induced acute liver injury model Intraperitoneal injection 10 mg/kg Single dose, 30 minutes SU3327 pretreatment significantly reduced p-JNK levels, mitochondrial phosphoprotein levels, and liver damage Redox Biol. 2015 Dec;6:552-564
ICR mice CCl4-induced acute liver injury model Intraperitoneal injection 10 mg/kg Single dose SU3327 significantly downregulated serum ALT and AST levels at 16 h post CCl4 injection, and concurrently blocked the activation of cPLA2. Sci Rep. 2020 Dec 17;10(1):22265
Male Sprague-Dawley rats Isolated heart Langendorff perfusion model, 25 min global ischemia followed by 30 min reperfusion Langendorff perfusion system 10 μM Continuous perfusion for 25 min pre-ischemia and during 30 min reperfusion To evaluate the effects of SU3327 on cardiac function and mitochondrial function. Results showed that SU3327 aggravated the recovery of heart function and reduced the mitochondrial respiratory control index. PLoS One. 2014 Nov 25;9(11):e113526
Mice Respiratory infection model Oral 25.48, 12.74, 6.37 mg/kg b.w. Single dose, lasting 48 hours Evaluate the in vivo antibacterial activity of SU3327, showing effective treatment of respiratory infections Antibiotics (Basel). 2024 May 27;13(6):492

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

3.83mL

0.77mL

0.38mL

19.14mL

3.83mL

1.91mL

38.27mL

7.65mL

3.83mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories